Advances in targeted delivery of small interfering RNA using simple bioconjugates

Bibliography

• Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys 2013;42:217-39
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
   PubMed Web of Science ®Google Scholar
• Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101(1):25-33
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15(2):188-200
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
   PubMed Web of Science ®Google Scholar
• Lewis DL, Hagstrom JE, Loomis AG, et al. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002;32(1):107-8
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002;418(6893):38-9
   PubMed Web of Science ®Google Scholar
• Juliano RL, Carver K, Cao C, et al. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J Drug Target 2013;21(1):27-43
   PubMed Web of Science ®Google Scholar
• Rajendran L, Knolker HJ, Simons K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 2010;9(1):29-42
   PubMed Web of Science ®Google Scholar
• Hammond SM, Bernstein E, Beach D, et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000;404(6775):293-6
   PubMed Web of Science ®Google Scholar
• Braasch DA, Paroo Z, Constantinescu A, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004;14(5):1139-43
   PubMed Web of Science ®Google Scholar
• Gao S, Dagnaes-Hansen F, Nielsen EJ, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 2009;17(7):1225-33
   PubMed Web of Science ®Google Scholar
• Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18(4):305-19
   PubMed Web of Science ®Google Scholar
• Bramsen JB, Kjems J. Development of therapeutic-grade small interfering RNAs by chemical engineering. Front Genet 2012;3:154
   PubMedGoogle Scholar
• Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000;97(10):5633-8
   PubMed Web of Science ®Google Scholar
• Elmen J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005;33(1):439-47
   PubMed Web of Science ®Google Scholar
• Langkjaer N, Pasternak A, Wengel J. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 2009;17(15):5420-5
   PubMed Web of Science ®Google Scholar
• Laursen MB, Pakula MM, Gao S, et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 2010;6(5):862-70
   PubMed Web of Science ®Google Scholar
• Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003;42(26):7967-75
   PubMed Web of Science ®Google Scholar
• Allerson CR, Sioufi N, Jarres R, et al. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 2005;48(4):901-4
   PubMed Web of Science ®Google Scholar
• Hall AH, Wan J, Shaughnessy EE, et al. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 2004;32(20):5991-6000
   PubMed Web of Science ®Google Scholar
• Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999;1489(1):69-84
   PubMed Web of Science ®Google Scholar
• Ui-Tei K, Naito Y, Zenno S, et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008;36(7):2136-51
   PubMed Web of Science ®Google Scholar
• Bramsen JB, Laursen MB, Nielsen AF, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009;37(9):2867-81
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8
   PubMed Web of Science ®Google Scholar
• Iversen F, Yang C, Dagnaes-Hansen F, et al. Optimized siRNA-PEG Conjugates for Extended Blood Circulation and Reduced Urine Excretion in Mice. Theranostics 2013;3(3):201-9
   PubMed Web of Science ®Google Scholar
• Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010;123(Pt 8):1183-9
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140(6):805-20
   PubMed Web of Science ®Google Scholar
• Weber F, Wagner V, Rasmussen SB, et al. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 2006;80(10):5059-64
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Dahlman JE, Langer RS, et al. Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng 2011;2:77-96
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11(3):263-70
   PubMed Web of Science ®Google Scholar
• Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23(4):457-62
   PubMed Web of Science ®Google Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9(1):57-67
   PubMed Web of Science ®Google Scholar
• Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem 2009;284(27):17897-901
   PubMed Web of Science ®Google Scholar
• Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias (vol 115, pg 209, 2003). Cell 2003;115(4):505-5
   Web of Science ®Google Scholar
• Schwarz DS, Hutvagner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115(2):199-208
   PubMed Web of Science ®Google Scholar
• Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. Rna 2006;12(7):1179-87
   PubMed Web of Science ®Google Scholar
• Bramsen JB, Pakula MM, Hansen TB, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 2010;38(17):5761-73
   PubMed Web of Science ®Google Scholar
• Bramsen JB, Laursen MB, Damgaard CK, et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007;35(17):5886-97
   PubMed Web of Science ®Google Scholar
• Fromontracine M, Bertrand E, Pictet R, et al. A Highly Sensitive Method for Mapping the 5' Termini of Messenger-Rnas. Nucleic Acids Res 1993;21(7):1683-4
   PubMed Web of Science ®Google Scholar
• Shi B, Keough E, Matter A, et al. Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J Histochem Cytochem 2011;59(8):727-40
   PubMed Web of Science ®Google Scholar
• Tanaka T, Shiramoto S, Miyashita M, et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004;277(1-2):39-61
   PubMedGoogle Scholar
• Bartlett DW, Su H, Hildebrandt IJ, et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007;104(39):15549-54
   PubMed Web of Science ®Google Scholar
• Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010;62(1):12-27
   PubMed Web of Science ®Google Scholar
• Hobel S, Aigner A. Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. Methods Mol Biol 2010;623:283-97
   Google Scholar
• Ewert KK, Ahmad A, Evans HM, et al. Cationic lipid-DNA complexes for non-viral gene therapy: relating supramolecular structures to cellular pathways. Expert Opin Biol Ther 2005;5(1):33-53
   PubMed Web of Science ®Google Scholar
• Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-301
   PubMed Web of Science ®Google Scholar
• Benjaminsen RV, Mattebjerg MA, Henriksen JR, et al. The possible "proton sponge " effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther 2013;21(1):149-57
   PubMed Web of Science ®Google Scholar
• Varkouhi AK, Scholte M, Storm G, et al. Endosomal escape pathways for delivery of biologicals. J Control Release 2011;151(3):220-8
   PubMed Web of Science ®Google Scholar
• Young JA, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007;76:243-65
   PubMed Web of Science ®Google Scholar
• Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987;56:365-94
   PubMed Web of Science ®Google Scholar
• Amarzguioui M, Lundberg P, Cantin E, et al. Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc 2006;1(2):508-17
   PubMed Web of Science ®Google Scholar
• Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5(11):886-97
   PubMed Web of Science ®Google Scholar
• Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem FEBS 2000;267(20):6102-9
   PubMedGoogle Scholar
• Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31(11):2705-16
   PubMed Web of Science ®Google Scholar
• Shah S, Friedman SH. Tolerance of RNA interference toward modifications of the 5' antisense phosphate of small interfering RNA. Oligonucleotides 2007;17(1):35-43
   PubMed Web of Science ®Google Scholar
• Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346(6287):818-22
   PubMed Web of Science ®Google Scholar
• Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249(4968):505-10
   PubMed Web of Science ®Google Scholar
• Robertson DL, Joyce GF. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 1990;344(6265):467-8
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011;21(1):1-10
   PubMed Web of Science ®Google Scholar
• Thiel KW, Giangrande PH. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 2009;19(3):209-22
   PubMed Web of Science ®Google Scholar
• Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 2005;16(9):1097-109
   PubMed Web of Science ®Google Scholar
• Wheeler LA, Trifonova R, Vrbanac V, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 2011;121(6):2401-12
   PubMed Web of Science ®Google Scholar
• Neff CP, Zhou J, Remling L, et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 2011;3(66):66ra6
   PubMed Web of Science ®Google Scholar
• Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008;16(8):1481-9
   PubMed Web of Science ®Google Scholar
• Zhou J, Swiderski P, Li H, et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009;37(9):3094-109
   PubMed Web of Science ®Google Scholar
• Chu TC, Twu KY, Ellington AD, et al. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006;34(10):e73
   PubMed Web of Science ®Google Scholar
• Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009;27(9):839-49
   PubMed Web of Science ®Google Scholar
• McNamara JO II, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24(8):1005-15
   PubMed Web of Science ®Google Scholar
• Thiel KW, Hernandez LI, Dassie JP, et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 2012;40(13):6319-37
   PubMed Web of Science ®Google Scholar
• Zhou J, Tiemann K, Chomchan P, et al. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res 2013;41(7):4266-83
   PubMed Web of Science ®Google Scholar
• Berezhnoy A, Brenneman R, Bajgelman M, et al. Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition. Mol Ther Nucleic Acids 2012;1:e51
   Google Scholar
• Kortylewski M, Swiderski P, Herrmann A, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009;27(10):925-32
   PubMed Web of Science ®Google Scholar
• Lorenz C, Hadwiger P, John M, et al. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004;14(19):4975-7
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-8
   PubMed Web of Science ®Google Scholar
• Kim WJ, Christensen LV, Jo S, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 2006;14(3):343-50
   PubMed Web of Science ®Google Scholar
• DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007;104(43):17204-9
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25(10):1149-57
   PubMed Web of Science ®Google Scholar
• Nishina K, Unno T, Uno Y, et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008;16(4):734-40
   PubMed Web of Science ®Google Scholar
• Uno Y, Piao W, Miyata K, et al. High-density lipoprotein facilitates in vivo delivery of alpha-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther 2011;22(6):711-19
   PubMed Web of Science ®Google Scholar
• Bang EK, Jeon EM, Kim W, et al. Tissue specific delivery of estrone-conjugated siRNAs. Mol Biosyst 2013;9(5):974-7
   PubMed Web of Science ®Google Scholar
• Filardo E, Quinn J, Pang Y, et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007;148(7):3236-45
   PubMed Web of Science ®Google Scholar
• Maxfield FR, Wustner D. Intracellular cholesterol transport. J Clin Invest 2002;110(7):891-8
   PubMed Web of Science ®Google Scholar
• Davidson TJ, Harel S, Arboleda VA, et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 2004;24(45):10040-6
   PubMed Web of Science ®Google Scholar
• Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004;558(1-3):63-8
   PubMed Web of Science ®Google Scholar
• Turner JJ, Jones S, Fabani MM, et al. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis 2007;38(1):1-7
   PubMed Web of Science ®Google Scholar
• Chiu YL, Ali A, Chu CY, et al. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004;11(8):1165-75
   PubMed Web of Science ®Google Scholar
• Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012;18(7):385-93
   PubMed Web of Science ®Google Scholar
• Overhoff M, Sczakiel G. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep 2005;6(12):1176-81
   PubMed Web of Science ®Google Scholar
• Detzer A, Overhoff M, Wunsche W, et al. Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. Rna 2009;15(4):627-36
   PubMed Web of Science ®Google Scholar
• Hsu T, Mitragotri S. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci USA 2011;108(38):15816-21
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448(7149):39-43
   PubMed Web of Science ®Google Scholar
• Kim SS, Ye C, Kumar P, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 2010;18(5):993-1001
   PubMed Web of Science ®Google Scholar
• Subramanya S, Kim SS, Abraham S, et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol 2010;84(5):2490-501
   PubMed Web of Science ®Google Scholar
• Jung HJ, Lim JS, Choi HJ, et al. Vasopressin V2R-targeting peptide carrier mediates siRNA delivery into collecting duct cells. PLoS One 2012;7(6):e40010
   Google Scholar
• Alam MR, Ming X, Fisher M, et al. Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem 2011;22(8):1673-81
   PubMed Web of Science ®Google Scholar
• Cesarone G, Edupuganti OP, Chen CP, et al. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug Chem 2007;18(6):1831-40
   PubMed Web of Science ®Google Scholar
• Zhu L, Mahato RI. Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem 2010;21(11):2119-27
   PubMed Web of Science ®Google Scholar
• Zhao XB, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008;5(3):309-19
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8(1):34-47
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23(6):709-17
   PubMed Web of Science ®Google Scholar
• Rowell JF, Stanhope PE, Siliciano RF. Endocytosis of endogenously synthesized Hiv-1 envelope protein - mechanism and role in processing for association with class-Ii Mhc. J Immunol 1995;155(1):473-88
   PubMed Web of Science ®Google Scholar
• Peer D, Zhu P, Carman CV, et al. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007;104(10):4095-100
   PubMed Web of Science ®Google Scholar
• Yao YD, Sun TM, Huang SY, et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2(+) breast cancer growth and metastasis. Sci Transl Med 2012;4:130
   PubMed Web of Science ®Google Scholar
• Wen WH, Liu JY, Qin WJ, et al. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 2007;46(1):84-94
   PubMed Web of Science ®Google Scholar
• Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134(4):577-86
   PubMed Web of Science ®Google Scholar
• Xia CF, Zhang Y, Zhang Y, et al. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007;24(12):2309-16
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012;1820(3):291-317
   PubMed Web of Science ®Google Scholar
• Ma Y, Kowolik CM, Swiderski PM, et al. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol 2011;6(9):962-70
   PubMed Web of Science ®Google Scholar
• Tu Z, Volk M, Shah K, et al. Constructing bioactive peptides with pH-dependent activities. Peptides 2009;30(8):1523-8
   PubMed Web of Science ®Google Scholar
• Midoux P, Kichler A, Boutin V, et al. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem 1998;9(2):260-7
   PubMed Web of Science ®Google Scholar
• Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem 2009;78:857-902
   PubMed Web of Science ®Google Scholar
• Canton I, Battaglia G. Endocytosis at the nanoscale. Chem Soc Rev 2012;41(7):2718-39
   PubMed Web of Science ®Google Scholar
• Akinc A, Battaglia G. Exploiting endocytosis for nanomedicines. Cold Spring Harb Perspect Biol 2013;5(11):a016980
   PubMed Web of Science ®Google Scholar
• Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011;6(9):1130-46
   PubMed Web of Science ®Google Scholar
• Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011;12(5):329-40
   PubMed Web of Science ®Google Scholar
• Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3(4):406-17
   PubMed Web of Science ®Google Scholar
• Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008;118(7):743-53
   PubMed Web of Science ®Google Scholar
• Hair P, Cameron F, McKeage K. Mipomersen sodium: first global approval. Drugs 2013;73(5):487-93
   PubMed Web of Science ®Google Scholar
• Anderson KP, Fox MC, Brown-Driver V, et al. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 1996;40(9):2004-11
   PubMed Web of Science ®Google Scholar